Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B
暂无分享,去创建一个
R. Chaisson | C. Thio | S. Charalambous | A. Grant | G. Churchyard | K. Fielding | C. Hoffmann | Desmond J. Martin | L. Pemba
[1] S. Charalambous,et al. Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy , 2007, Psychology, health & medicine.
[2] R. Chaisson,et al. Establishing a workplace antiretroviral therapy programme in South Africa , 2007, AIDS care.
[3] S. Eholie,et al. Tolerance and Acceptability of an Efavirenz-Based Regimen in 740 Adults (Predominantly Women) in West Africa , 2006, Journal of acquired immune deficiency syndromes.
[4] M. Matee,et al. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar Es Salaam, Tanzania , 2006, BMC public health.
[5] R. Chaisson,et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. , 2005, JAMA.
[6] I. Kanfer,et al. African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology , 2005, Nutrition journal.
[7] M. Lederman,et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. , 2005, The Journal of infectious diseases.
[8] V. Soriano,et al. Hepatotoxicity of Antiretrovirals , 2005, Drug safety.
[9] F. Dabis,et al. HBV and HCV prevalence and viraemia in HIV‐positive and HIV‐negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study , 2004, Journal of medical virology.
[10] B. Gazzard,et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.
[11] D. Dieterich,et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] K. Ruxrungtham,et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 , 2003, AIDS.
[13] Richard D Moore,et al. Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV Cohort , 2003, Journal of acquired immune deficiency syndromes.
[14] C. Fang,et al. Human immunodeficiency virus‐1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing , 2003, Vox sanguinis.
[15] N. Crowther,et al. The cytotoxic effects of a traditional Zulu remedy, impila (Callilepis laureola) , 2002, Human & experimental toxicology.
[16] S. Sutcliffe,et al. HIV‐1 Prevalence and Herpes Simplex Virus 2, Hepatitis C Virus, and Hepatitis B Virus Infections Among Male Workers at a Sugar Estate in Malawi , 2002, Journal of acquired immune deficiency syndromes.
[17] F. Wit,et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. , 2002, The Journal of infectious diseases.
[18] R. Hayes,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Hiv-1/aids and the Control of Other Infectious Diseases in Africa , 2022 .
[19] B. Stricker,et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort , 2002, AIDS.
[20] N. Ives,et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy , 2002, AIDS.
[21] R. Chaisson,et al. Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.
[22] D. Snydman,et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] B. Schoub,et al. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. , 2009, East African medical journal.
[24] P. Reiss,et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.
[25] R. Chaisson,et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.
[26] C. Chu,et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.
[27] M. Tanner,et al. Prevalence and mother‐to‐infant transmission of hepatitis viruses B, C, and E in Southern Tanzania , 1999, Journal of medical virology.